title: Re: Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor: M. Shiota, K. Kiyoshima, A. Yokomizo, A. Takeuchi, E. Kashiwagi, T. Dejima, R. Takahashi, J. Inokuchi, K. Tatsugami and M. Eto J Urol 2017;197:308-313.
authors.affiliation: Department of Urology, Stanford University Medical Center, Stanford, California; Department of Urology, Soonchunhyang University Hospital, Soonchuhyang University Medical College, Seoul, Korea. Electronic address: piacekjh@hanmail.net.
authors.forename: Jae Heon
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Department of Urology, Stanford University Medical Center, Stanford, California; Department of Urology, Soonchunhyang University Hospital, Soonchuhyang University Medical College, Seoul, Korea.
authors.forename: Benjamin I
authors.initials: BI
authors.lastname: Chung
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D006801:Humans; D009364:Neoplasm Recurrence, Local; D010088:Oxidoreductases; D001749:Urinary Bladder Neoplasms
chemical_list: D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D010088:Oxidoreductases